{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T22:45:16Z","timestamp":1649025916389},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11908-004-0008-3","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:05:30Z","timestamp":1180058730000},"page":"191-199","source":"Crossref","is-referenced-by-count":3,"title":["The use of ketolides in treatment of upper respiratory tract infections"],"prefix":"10.1007","volume":"6","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra K.","family":"Wierzbowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiko","family":"Hisanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1517\/14656566.3.3.277","volume":"3","author":"GG Zhanel","year":"2002","unstructured":"Zhanel GG, Hoban DJ: Ketolides in the treatment of respiratory infections. Expert Opin Pharmacother 2002, 3:277\u2013297. This review discusses the use of ketolides in the treatment of RTI.","journal-title":"Expert Opin Pharmacother"},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003495-200161040-00003","volume":"61","author":"GG Zhanel","year":"2001","unstructured":"Zhanel GG, Dueck M, Hoban DJ, et al.: Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001, 61:443\u2013498. This is a comprehensive review of macrolide and ketolide mechanism of action and resistance.","journal-title":"Drugs"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/00003495-200262120-00006","volume":"62","author":"GG Zhanel","year":"2002","unstructured":"Zhanel GG, Walters M, Noreddin A, et al.: The ketolides: a critical review. Drugs 2002, 62:1771\u20131804. This is a very detailed analysis of ketolide mechanisms of action and resistance, in vitro activity, pharmacokinetics\/pharmacodynamics, and adverse effects, highlighting the differences found for macrolides.","journal-title":"Drugs"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1517\/14728214.8.2.297","volume":"8","author":"GG Zhanel","year":"2003","unstructured":"Zhanel GG, Hisanaga T, Nichol K, et al.: Ketolides: an emerging treatment for macrolide-resistant respiratory tract infections, focusing on S. pneumoniae. Expert Opin Emerg Drugs 2003, 8:297\u2013321. This is a comprehensive and comparative review of ketolide versus macrolide mechanism of action and resistance, pharmacokinetics\/ pharmacodynamics, clinical trials, and adverse effects.","journal-title":"Expert Opin Emerg Drugs"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1469-0691.2000.00185.x","volume":"6","author":"A Bryskier","year":"2000","unstructured":"Bryskier A: Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000, 6:661\u2013669.","journal-title":"Clin Microbiol Infect"},{"key":"8_CR6","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1128\/AAC.44.6.1562-1567.2000","volume":"44","author":"JO Capobianco","year":"2000","unstructured":"Capobianco JO, Cao Z, Shortridge VD, et al.: Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000, 44:1562\u20131567.","journal-title":"Antimicrob Agents Chemother"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.289.5481.905","volume":"289","author":"N Ban","year":"2000","unstructured":"Ban N, Nissen P, Hansen J, et al.: The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science 2000, 289:905\u2013920.","journal-title":"Science"},{"key":"8_CR8","first-page":"203","volume":"42","author":"WS Champney","year":"2001","unstructured":"Champney WS, Tober CL: Structure-activity relationships for six ketolide antibiotics. Curr Microbiol 2001, 42:203\u2013210.","journal-title":"Curr Microbiol"},{"key":"8_CR9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/PL00006814","volume":"38","author":"WS Champney","year":"1999","unstructured":"Champney WS, Tober CL: Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 1999, 38:342\u2013348.","journal-title":"Curr Microbiol"},{"key":"8_CR10","unstructured":"Novotny GW, Andersen NM, Poehlsgaard J: Telithromycin interacts directly with the base of A752 in domain II of 23S ribosomal RNA, in contrast to erythromycin and clarithromycin [abstract P480]. In 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey: 2001."},{"key":"8_CR11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","volume":"31","author":"LH Hansen","year":"1999","unstructured":"Hansen LH, Mauvais P, Douthwaite S: The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999, 31:623\u2013631.","journal-title":"Mol Microbiol"},{"key":"8_CR12","unstructured":"Douthwaite S, Mauvais P, Champney WS, Bryskier A: Structureactivity relationship of the ketolide telithromycin (HMR 3647) [abstract 02.02]. In 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones. Seville, Spain: 2000."},{"key":"8_CR13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2958.2000.01841.x","volume":"36","author":"S Douthwaite","year":"2000","unstructured":"Douthwaite S, Hansen LH, Mauvais P: Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000, 36:183\u2013193.","journal-title":"Mol Microbiol"},{"key":"8_CR14","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1128\/AAC.43.12.2823","volume":"43","author":"MC Roberts","year":"1999","unstructured":"Roberts MC, Sutcliffe J, Courvalin P, et al.: Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999, 43:2823.","journal-title":"Antimicrob Agents Chemother"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1128\/AAC.44.12.3395-3401.2000","volume":"44","author":"A Tait-Kamradt","year":"2000","unstructured":"Tait-Kamradt A, Davies T, Appelbaum PC, et al.: Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000, 44:3395\u20133401.","journal-title":"Antimicrob Agents Chemother"},{"key":"8_CR16","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.44.8.2118-2125.2000","volume":"44","author":"A Tait-Kamradt","year":"2000","unstructured":"Tait-Kamradt A, Davies T, Cronan M, et al.: Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000, 44:2118\u20132125.","journal-title":"Antimicrob Agents Chemother"},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/40.1.85","volume":"40","author":"A Bonnefoy","year":"1997","unstructured":"Bonnefoy A, Girard AM, Agouridas C, Chantot JF: Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997, 40:85\u201390.","journal-title":"J Antimicrob Chemother"},{"key":"8_CR18","unstructured":"Mauvais P, Bonnefoy A: Lack of in vitro MLSB resistance induction by the ketolide telithromycin (HMR 3647): role of the 3-keto group [abstract 02.10]. In 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones. Seville, Spain: 2000."},{"key":"8_CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000066766","volume":"48","author":"C Perret","year":"2002","unstructured":"Perret C, Lenfant B, Weinling E, et al.: Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy 2002, 48:217\u2013223.","journal-title":"Chemotherapy"},{"key":"8_CR20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/AAC.45.1.23-29.2001","volume":"45","author":"I Odenholt","year":"2001","unstructured":"Odenholt I, Lowdin E, Cars O: Pharmacodynamics of telithromycin: in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001, 45:23\u201329.","journal-title":"Antimicrob Agents Chemother"},{"key":"8_CR21","unstructured":"Sultan E, Namour F, Mauriac C, et al.: The ketolide antimicrobial, telithromycin (HMR 3647), is metabolized and eliminated predominantly in the faeces in man [abstract 09.31]. In 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones. Seville, Spain: 2000."},{"key":"8_CR22","unstructured":"Sharma K, Katgely B, Villa R, Pluim J: Safety profile of the first ketolide antimicrobial, telithromycin: a review [abstract P17.018]. In 22nd International Congress of Chemotherapy. Amsterdam, The Netherlands: 2001."},{"key":"8_CR23","volume-title":"Antimicrobial Agents.","author":"GG Zhanel","year":"2004","unstructured":"Zhanel GG, Neuhauser M: The ketolides. In Antimicrobial Agents. Edited by Yu V, McKinnon N. New York: Lippincott, Williams and Wilkins; 2004, In press. This is a ketolide review with great emphasis on drug-drug interaction, adverse side effects, effects of disease states and host immunity, and brief indications for treatment of upper and lower RTIs."},{"key":"8_CR24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/340949","volume":"35","author":"AL Bisno","year":"2002","unstructured":"Bisno AL, Gerber MA, Gwaltney JM Jr, et al.: Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002, 35:113\u2013125.","journal-title":"Clin Infect Dis"},{"key":"8_CR25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0732-8893(98)00155-2","volume":"33","author":"C Betriu","year":"1999","unstructured":"Betriu C, Casado MC, Gomez M, et al.: Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study. Diagn Microbiol Infect Dis 1999, 33:255\u2013260.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"8_CR26","unstructured":"Norrby S, Rabie W, Bacart P, et al.: Efficacy of 5 days\u2019 telithromycin (HMR 3647) vs 10 days\u2019 penicillin V in the treatment of pharyngitis in adults [abstract 2242]. Paper presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17\u201320, 2000."},{"key":"8_CR27","unstructured":"Chang J, Stewart J, Brumpt I, et al.: Telithromycin (HMR 3647) provides more rapid relief from symptoms than penicillin V in patients with GABHS pharyngitis [abstract P1262]. In 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey: 2001."},{"key":"8_CR28","unstructured":"Quinn J, Ziter P, Leroy B, et al.: Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well tolerated and as effective as oral clarithromycin 250 mg twice daily for 10 days in group A-hemolytic streptococcal (GABHS) pharyngitis\/ tonsillitis [abstract 2229]. Paper presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17\u201320, 2000."},{"key":"8_CR29","unstructured":"Roos K, Brunswig-Pitschner C, Kostrica R, et al.: Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis [abstract 2243]. Paper presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17\u201320, 2000."},{"key":"8_CR30","unstructured":"Buchanan P, McNeil D, Tady D, et al.: A 5-day course of telithromycin, the first ketolide antibacterial, is as effective as 10 days cefuroxime axetil in the treatment of acute maxillary sinusitis [abstract 910]. In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: 2001."},{"key":"8_CR31","unstructured":"Tellier G, Lasko B, Leroy B, et al.: Oral telithromycin (HMR 3647) 800 mg once daily for 5 days and 10 days is well tolerated and as effective as amoxicillin\/clavulanic acid 500\/125 mg three times daily for 10 days in acute maxillary sinusitis (AMS) in adults [abstract 2226]. Paper presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17\u201320, 2000."}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-004-0008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-004-0008-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-004-0008-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:21:59Z","timestamp":1559434919000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-004-0008-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s11908-004-0008-3","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}